View Post

Local Surgeon Reports Positive Findings from Use of 3D Marker in Breast Cancer Treatment

In In The News by Barbara Jacoby0 Comments

Better Cosmetic Outcomes and Shorter Radiation Therapy Seen in Study Results A research study by local surgical oncologist Michael Cross, M.D., F.A.C.S., concluded that use of the BioZorb® surgical marker appears to provide better cosmetic outcomes and may be associated with an increased use of breast-conserving surgery in his practice. The study found that more than 90% of patients who …

View Post

Does Low-Dose Aspirin Reduce Risk of Breast Cancer?

In In The News by Barbara Jacoby0 Comments

By: Jennifer Barrett, Assistant Editor From: pharmacytimes.com Low-dose aspirin may help women reduce their risk of developing breast cancer, a new study published in Breast Cancer Research has suggested.1 Overall, regular low-dose aspirin use (81 mg) was tied to a 16% lower risk of breast cancer in women when taken at least 3 times per week. The study, led by …

View Post

Contemporary Inflammatory Breast Cancer Therapy Yields Low Local/Regional Recurrence

In In The News by Barbara Jacoby0 Comments

From: The American Society of Breast Surgeons Aggressive Triple-Modality Therapy Prevents Cancer from Returning in the Chest Wall and Lymph Nodes Current triple-modality therapy for highly aggressive inflammatory breast cancer achieved a 95.5% five-year survival rate with no local cancer recurrence, similar to other breast cancers, in a new study presented this week at the Annual Meeting of the American …

View Post

Debunking the Myth of Lymphedema Risk

In In The News by Barbara Jacoby0 Comments

From: The American Society of Breast Surgeons Axillary Surgery Only One Factor Breast cancer-related lymphedema, chronic swelling of the arm and chest area, is strongly associated with multi-modality therapies and not axillary node surgery alone as widely believed, according to a new study presented this week at the Annual Meeting of the American Society of Breast Surgeons. The study found …

View Post

Texas House Passes HB 1036 – 3-D Mammography Coverage

In In The News by Barbara Jacoby0 Comments

Texas House Bill 1036 passed the House of Representatives with strong support today. The bill will now proceed to the Texas Senate for a vote. The bill passed unanimously through the state’s Insurance Committee earlier this month. If the bill is passed by the Texas Senate and signed by Texas Governor Greg Abbott into law, it will require all commercial …

View Post

New therapy reduces treatment time for breast cancer patients

In In The News by Barbara Jacoby0 Comments

Source: Ivanhoe News Service From: abc7chicago.com The American Cancer Society estimates more than a quarter million people will be diagnosed with breast cancer in the U.S. this year. Many of them will get weeks of radiation after surgery. A new option that eliminates that extra treatment time for early stage patients. Judy Collins was 80 when she learned she had …

View Post

Simon Continues More Than Pink™ Drive With Susan G. Komen® To Reduce Breast Cancer Deaths In The U.S. By 50 Percent By 2026

In In The News by Barbara Jacoby0 Comments

From: PR Newswire Simon Malls, The Mills and Premium Outlets offering discount cards, hosting project:OM yoga events and more during Spring drive Simon, a global leader in retail real estate, today announced its Spring 2017 More Than Pink movement in support of Susan G. Komen and the fight against breast cancer. As part of its pledge to donate $1 million …

View Post

Tumor ‘Paint’ Aids Breast Cancer Surgeons and Well-Tolerated by Patients, Study Reports

In In The News by Barbara Jacoby0 Comments

By: Janet Stewart, MSc From: breastcancer-news.com BLZ-100 (tozuleristide) was found to be well-tolerated by patients and to make breast cancer tumors more easily seen during surgery in a Phase 1 clinical trial, Blaze Bioscience announced. BLZ-100 was used to “paint” tumors to better guide surgeons while operating. Results of the trial (NCT02496065) were presented at the American Society of Breast Surgeons …

View Post

Novartis receives FDA approval for first-of-its-kind Kisqali® Femara® Co-Pack for initial treatment of HR+/HER2- advanced or metastatic breast cancer

In In The News by Barbara Jacoby0 Comments

From: PR Newswire — Physicians now have the option of prescribing Kisqali and Femara together in one convenient co-pack — Co-Pack allows patients ability to obtain Kisqali and Femara with a single co-pay — Approval comes less than two months after Kisqali received US FDA approval  Novartis announced today that the US Food and Drug Administration (FDA) has approved the …